FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:627-633 March 9, 1989 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

More accurate prediction of the prognosis in women with node-negative breast cancer may improve physicians' ability to identify the patients most likely to benefit from systematic adjuvant therapy. With this in mind, we performed DNA flow-cytometric measurements of ploidy and the fraction of cells in the synthesis phase of the cell cycle (S-phase fraction) on 395 specimens of node-negative breast cancer from our bank of frozen tumors, using the aliquots of pulverized frozen tissue from steroid-receptor assays. The median duration of follow-up in patients still alive at the time of analysis was 59 months. Thirty-two percent of the 345 specimens that could be evaluated were diploid, and 68 percent were aneuploid. The probability of disease-free survival at five years was 88 +/- 3 percent in patients with diploid tumors and 74 +/- 3 percent in those with aneuploid tumors (P = 0.02). The S-phase fraction was not a significant additional predictor of disease-free survival in patients with aneuploid tumors. However, the probability of disease-free survival in patients with diploid tumors and low S-phase fractions was 90 +/- 3 percent at five years, as compared with 70 +/- 13 percent in those with diploid tumors and high S-phase fractions (P = 0.007). Similar differences in overall survival were noted. We conclude that DNA flow-cytometric measurements of ploidy and S-phase fraction can be performed on frozen specimens of tumors and are potentially important predictors of disease-free and overall survival in patients with node-negative breast cancer.

Source Information

Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7884.

This article has been cited by other articles:

• Pinto, A E, Roque, L, Rodrigues, R, Andre, S, Soares, J (2006). Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation. J. Clin. Pathol. 59: 367-372 [Abstract] [Full Text]  
• Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., Piccart, M. J. (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 16: 1723-1739 [Abstract] [Full Text]  
• Arpino, G., Weiss, H.L., Clark, G.M., Hilsenbeck, S.G., Osborne, C.K. (2005). Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen. JCO 23: 4687-4694 [Abstract] [Full Text]  
• Isaka, T., Nestor, A. L., Takada, T., Allison, D. C. (2003). Chromosomal Variations Within Aneuploid Cancer Lines. J. Histochem. Cytochem. 51: 1343-1353 [Abstract] [Full Text]  
• Ibrahim, A E K, Bateman, A C, Theaker, J M, Low, J L, Addis, B, Tidbury, P, Rubin, C, Briley, M, Royle, G T (2001). The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions. J. Clin. Pathol. 54: 121-125 [Abstract] [Full Text]  
• Reed, D. N. Jr, Johnson, J., Richard, P., McCormick, S., Shannon, N., Mikhail, R. A., Osuch, J., Cerrito, P. B., McMasters, K. M. (2000). DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer. Arch Surg 135: 1422-1426 [Abstract] [Full Text]  
• Diab, S. G., Elledge, R. M., Clark, G. M. (2000). Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer. JNCI J Natl Cancer Inst 92: 550-556 [Abstract] [Full Text]  
• Chang, J., Powles, T. J., Allred, D. C., Ashley, S. E., Clark, G. M., Makris, A., Assersohn, L., Gregory, R. K., Osborne, C. K., Dowsett, M. (1999). Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer. JCO 17: 3058-3063 [Abstract] [Full Text]  
• Placido, S. D., Carlomagno, C., Ciardiello, F., Laurentiis, M. D., Pepe, S., Ruggiero, A., Tortora, G., Panico, L., D'Antonio, A., Pettinato, G., Petrella, G., Bianco, A. R. (1999). Measurement of Neovascularization Is an Independent Prognosticator of Survival in Node-negative Breast Cancer Patients with Long-Term Follow-Up. Clin. Cancer Res. 5: 2854-2859 [Abstract] [Full Text]  
• Jatoi, I., Hilsenbeck, S. G., Clark, G. M., Osborne, C. K. (1999). Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer. JCO 17: 2334-2334 [Abstract] [Full Text]  
• Hebbar, M., Revillion, F., Louchez, M.-M., Fournier, C., Bonneterre, J., Peyrat, J.-P. (1999). Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients. Clin. Cancer Res. 5: 1427-1433 [Abstract] [Full Text]  
• Diab, S. G., Clark, G. M., Osborne, C. K., Libby, A., Allred, D. C., Elledge, R. M. (1999). Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas. JCO 17: 1442-1442 [Abstract] [Full Text]  
• Harvey, J. M., Clark, G. M., Osborne, C. K., Allred, D. C. (1999). Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. JCO 17: 1474-1474 [Abstract] [Full Text]  
• Cobleigh, M. A., Norlock, F. E., Oleske, D. M., Starr, A. (1999). Hormone Replacement Therapy and High S Phase in Breast Cancer. JAMA 281: 1528-1530 [Abstract] [Full Text]  
• Brenin, D. R., Talamonti, M. S., Yang, E. Y. T., Sener, S. F., Haines, G. K., Joehl, R. J., Nahrwold, D. L. (1995). Cystic Neoplasms of the Pancreas: A Clinicopathologic Study, Including DNA Flow Cytometry. Arch Surg 130: 1048-1054 [Abstract]  
• Gohring, U. J., Ahr, A., Scharl, A., Weisner, V., Neuhaus, W., Crombach, G., Holt, J. A. (1995). Immunohistochemical Detection of Epidermal Growth Factor Receptor Lacks Prognostic Significance for Breast Carcinoma. Reproductive Sciences 2: 653-659 [Abstract]  
• Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., Henderson, I. C. (1994). c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer. NEJM 330: 1260-1266 [Abstract] [Full Text]  
• Opitz, L. M., Vamvakas, E. C., Espiritu, E. C., Fineberg, S. A., Feiner, H. (1993). Proliferation Kinetics of Non-Hodgkin's Lymphoma: Correlation With Histologic Grade According to the International Working Formulation. INT J SURG PATHOL 1: 33-41 [Abstract]  
• (1993). Report of the Council on Scientific Affairs: Management of Patients With Node-Negative Breast Cancer. Arch Intern Med 153: 58-67 [Abstract]  
• Johnson, H. Jr, Masood, S., Belluco, C., Abou-Azama, A.-M., Dee, S., Kahn, L., Wise, L. (1992). Prognostic Factors in Node-Negative Breast Cancer. Arch Surg 127: 1386-1391 [Abstract]  
• Crowe, J. P. Jr, Gordon, N. H., Shenk, R. R., Zollinger, R. M. Jr, Brumberg, D. J., Shuck, J. M. (1992). Primary Tumor Size: Relevance to Breast Cancer Survival. Arch Surg 127: 910-916 [Abstract]  
• Armitage, J. O. (1992). Tumor Proliferative Rate and Response to Chemotherapy. ANN INTERN MED 116: 771-773 [Abstract]  
• Goodson, W. H. III, Ljung, B.-M., Waldman, F., Mayall, B., Chew, K., Moore, D. H. II, Smith, H., Goldman, E. S., Benz, C. (1991). In Vivo Measurement of Breast Cancer Growth Rate. Arch Surg 126: 1220-1224 [Abstract]  
• Moffat, F. L., Ketcham, A. S., Robinson, D. S., Legaspi, A., Ghandur-Mnaymneh, L., Hilsenbeck, S. (1990). Segmental Mastectomy Without Radiotherapy for T1 and Small T2 Breast Carcinomas. Arch Surg 125: 364-369 [Abstract]  
• Donohue, J. H., Nagorney, D. M., Grant, C. S., Tsushima, K., Ilstrup, D. M., Adson, M. A. (1990). Carcinoma of the Gallbladder: Does Radical Resection Improve Outcome?. Arch Surg 125: 237-241 [Abstract]